Abstract:Pharmaceuticals are recognised among emerging contaminants, particularly in water. They have the potential to alter ecosystem dynamics, with notable examples including hormone-induced feminization of male fish and disruptions to oogenesis in invertebrates. To assess the risk posed by pharmaceuticals, it is essential to understand their amount (via Measured Environmental Concentrations MEC) and their actual effects on target species (via Predicted No Effect Concentrations PNEC). Recently, many studies have aimed to collect MEC data from around the world, but a comprehensive overview is still lacking. Thus, the objective of this study is to provide a comprehensive overview by examining recently published literature on MEC data for a wide range of pharmaceuticals. Additionally, to enable risk assessment, this study also reviewed the published literature on PNEC data and integrated it with existing databases. A total of 315 substances were selected for MEC data extraction, with the inclusion of 56 articles. The most frequently monitored locations were Cadiz Bay in Spain (90 samples), the River Thames in the UK (51), and Hrdějovice in the Czech Republic (49). Most MEC samples were collected from surface water (N=325), influent wastewater treatment plants (WWTP) (205), and effluent WWTP (118). Based on PNEC values, risk analysis identified 81 pharmaceuticals as high-risk, with the highest risk values for propranolol (risk quotient [RQ]: 29,450,000), diclofenac (395,920), and 17alpha-ethinylestradiol (95,946). Additionally, the ATC classes with the most high-risk substances were anti-infectives (J), nervous system agents (N), cardiovascular agents (C), antineoplastic agents (L), analgesics (M), and sex hormones (G). The findings of this study highlight the widespread impact of pharmaceuticals across the globe and the involvement of multiple therapeutic classes. To move beyond the current point-in-time overview, which is limited to specific locations and sampling periods, systems for continuous monitoring of pharmaceuticals should be developed. This could involve the creation of resource-efficient methods and the integration of sampling data with estimation models. Furthermore, these results could serve as a starting point for developing and implementing actions to prevent and mitigate the environmental impact of pharmaceuticals.

The impact of pharmaceutical pollutants on daphnids - A metabolomic approach

Emerging challenges of the impacts of pharmaceuticals on aquatic ecosystems: A diatom perspective

Metabolomic study on ostracods exposed to environmentally relevant concentrations of five pharmaceuticals selected via a novel approach

The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects

Metabolomic‐Based Comparison of Daphnia magna and Japanese Medaka Responses After Exposure to Acetaminophen, Diclofenac, and Ibuprofen

Targeted metabolomics of Gammarus pulex following controlled exposures to selected pharmaceuticals in water

A review of the effects of pharmaceutical pollutants on humans and aquatic ecosystem

Temporal Analysis of Pharmaceuticals as Emerging Contaminants in Surface Water and Wastewater Samples: A Case Study

The impact of amine and carboxyl functionalised microplastics on the physiology of daphnids

Occurrence of pharmaceuticals in surface waters: analytical method development and environmental risk assessment

Biomonitoring emerging hazards of pharmaceuticals in river water using gut microbiome and behavioural Daphnia magna responses

Toxicity of selected pharmaceuticals and their mixtures to the aquatic indicators Daphnia magna and Aliivibrio fischeri

Combined effects of micropollutants and their degradation on prokaryotic communities at the sediment-water interface

[Pharmaceutical residues in aquatic compartments : Status quo and perspectives]

Developing an Approach for Integrating Chemical Analysis and Transcriptional Changes to Assess Contaminants in Water, Sediment, and Fish

Single and mixture toxicity of four pharmaceuticals of environmental concern to aquatic organisms, including a behavioral assessment

Emerging contaminants in the aquatic environment: phytoplankton structure in the presence of sulfamethoxazole and diclofenac

Prioritizing Pharmaceutical Contaminants in Great Lakes Tributaries Using Risk-Based Screening Techniques

Untargeted metabolomics changes on Gammarus pulex induced by propranolol, triclosan, and nimesulide pharmaceutical drugs

Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?

Determination of the pharmaceuticals-nano/microplastics in aquatic systems by analytical and instrumental methods